Cholesterol excess is typical of various diseases including atherosclerosis. We have investigated whether cholesterol accumulation in the ER (endoplasmic reticulum) can inhibit exit of vesicular cargo and secretion of proteins by studying apoE (apolipoprotein E), a significant glycoprotein in human health and disease. CHO (Chinese hamster ovary) cells expressing human apoE under a cholesterol-independent promoter incubated with cholesterol-cyclodextrin complexes showed increased levels of cellular free and esterified cholesterol, inhibition of SREBP-2 (sterol-regulatory-element-binding protein 2) processing, and a mild induction of ER stress, indicating significant accumulation of cholesterol in the ER. Secretion of apoE was markedly inhibited by cholesterol accumulation, and similar effects were observed in cells enriched with lipoprotein-derived cholesterol and in primary human macrophages. Removal of excess cholesterol by a cyclodextrin vehicle restored apoE secretion, indicating that the transport defect was reversible. That cholesterol impaired protein trafficking was supported by the cellular accumulation of less sialylated apoE glycoforms, and by direct visualization of altered ER to Golgi transport of thermo-reversible VSVG (vesicular stomatitis virus glycoprotein) linked to GFP (green fluorescent protein). We conclude that intracellular accumulation of cholesterol in the ER reversibly inhibits protein transport and secretion. Strategies to correct ER cholesterol may restore homoeostatic processes and intracellular protein transport in conditions characterized by cholesterol excess.
INTRODUCTION
Cholesterol is a vital component of cellular membranes and intracellular transport processes. Intracellular cholesterol levels are carefully regulated by feedback mechanisms that monitor membrane cholesterol content and control the transcription of genes mediating cholesterol biosynthesis and the uptake of lipoproteins [1] . Deficiency of cholesterol alters ER (endoplasmic reticulum) and Golgi structure and impedes intracellular vesicular transport [2] [3] [4] [5] . Cholesterol accumulation has been reported to interfere with movement from the TGN (trans-Golgi network) [6] , but whether cholesterol accumulation can perturb exit of vesicular cargo from the ER compartment is unclear.
Lipoprotein-and cell-derived cholesterol deposited in the intima during atherogenesis are internalized by various cell types, increasing intracellular cholesterol levels [7, 8] . Under these conditions of cholesterol excess, cholesterol is esterified in the ER compartment by microsomal ACAT (acetyl-CoA:acyl transferase) to generate CEs (cholesteryl esters), which accumulate within cytoplasmic lipid droplets. In addition, increased levels of FC (free cholesterol) can accumulate in cell membranes and induce ER stress. Although the ER stress pathways can restore cell homoeostasis, prolonged stress can lead to cell apoptosis and progression of atherosclerotic lesions [8] . As a consequence, intracellular transport and secretion of proteins carried as vesicular cargo could be perturbed by cholesterol accumulation. This includes the transport and secretion of glycoproteins such as apoE (apolipoprotein E), which follows the classical secretory pathway and which is implicated in Alzheimer's disease and atherosclerosis [9] [10] [11] .
CHO (Chinese hamster ovary) cells have yielded important insights into the regulation of cellular cholesterol metabolism and its regulation at the level of the ER by SCAP [SREBP (sterolregulatory-element-binding protein) cleavage-activating protein] and SREBP [12] . Their intracellular secretory machinery has been well studied, both in terms of the VSVGt [thermo-reversible VSVG (vesicular stomatitis virus glycoprotein)] transporter protein [13] [14] [15] and other cargoes such as apoE [16, 17] . Using complementary biochemical and microscopic techniques we report that cholesterol accumulation reversibly interferes with intracellular protein transport and secretion, and does so most probably at the level of ER to Golgi transport.
EXPERIMENTAL Materials
Methyl-β CD (cyclodextrin), compactin, mevalonate, Tun (tunicamycin), Thaps (thapsigargin), DTT (dithiothreitol), BFA (brefeldin A) and α-(2→3, 6, 8, 9 )-neuraminidase were purchased from Sigma, and T0901317 was obtained from Cayman Abbreviations used: ACAT, acetyl-CoA:acyl transferase; ACATi, ACAT inhibitor; apoE, apolipoprotein E; BFA, brefeldin A; CD, cyclodextrin; CE, cholesteryl ester; CHO, Chinese hamster ovary; chol/CD, cholesterol-CD; CMV, cytomegalovirus; COPII, coatamer protein II; 2-DE, two-dimensional gel electrophoresis; DMEM, Dulbecco's modified Eagle's medium; DTT, dithiothreitol; eIF2α, eukaryotic translation-initiation factor 2α; endo H, endoglycosidase H; ER, endoplasmic reticulum; FC, free cholesterol; GADD34, growth arrest and DNA-damage-inducible protein; GFP, green fluorescent protein; HMDM, human monocyte-derived macrophage; IRE1α, inositol-requiring 1α; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; LPDCS, lipoproteindeficient new-born bovine serum; LPDS, lipoprotein-deficient human serum; LXR, liver X receptor; SREBP, sterol-regulatory-element-binding protein; SCAP, SREBP cleavage-activating protein; TGN, trans-Golgi network; Thaps, thapsigargin; Tun, tunicamycin; VSVG, vesicular stomatitis virus glycoprotein; VSVGt, thermo-reversible VSVG. 1 To whom correspondence should be addressed (email leonard.kritharides@sydney.edu.au).
Chemicals. Rabbit polyclonal antibodies against phospho-(phosphorylated) IRE1α (inositol-requiring 1α), phosphoeIF2α (eukaryotic translation-initiation factor 2α) and hamster GADD34 (growth arrest and DNA-damage-inducible protein) were from Abcam, Cell Signaling Technology and Santa Cruz Biotechnology respectively. ApoE was detected using a goat polyclonal antibody directed against human apoE (Chemicon). The ACATi (ACAT inhibitor; Sandoz 58-035) was generously provided by Sandoz Pharmaceuticals. LDL (lowdensity lipoprotein), LPDS (lipoprotein-deficient human serum) and LPDCS (lipoprotein-deficient new-born bovine serum) were prepared as described previously [18, 19] .
Cells
CHO-K1 cells stably expressing and secreting human apoE (CHO-apoE) under a CMV (cytomegalovirus) promoter have been described previously [16] . A cell line stably expressing VSVGt linked to GFP (green fluorescent protein) was generated (GFP-VSVGt). SRD-13A cells [20] , a CHO cell line deficient in SCAP, were co-transfected with pGFP-VSVGt and a plasmid encoding SCAP. The cells expressing these plasmids were selected by supplying only lipoprotein-deficient medium. Cells were maintained in advanced DMEM (Dulbecco's modified Eagle's medium)/F12 (Invitrogen) medium containing 5 % LPDCS, 50 units/ml penicillin, 50 μg/ml streptomycin and 2 mM L-glutamine.
Primary HMDMs (human monocyte-derived macrophages) were generated as described previously [16] .
Cell viability was continually monitored by light microscopy and was measured by a LDH (lactate dehydrogenase) assay [21] to be >90 % in all of the experiments shown unless otherwise indicated.
Cholesterol loading
Cholesterol complexed to methyl-β CD was prepared as described previously [22] . Cells were washed twice and incubated with 20 μg/ml chol/CD (cholesterol-CD) complexes with or without ACATi in F12 medium containing 10 % LPDS for the indicated periods. Preliminary time-course experiments indentified that optimal cholesterol enrichment of CHO-apoE cells was achieved after overnight (16 h) incubation with chol/CD complexes, whereas CHO-GFP-VSVGt cells were optimally enriched after 2 h of incubation. Enrichment with cholesterol was directly confirmed by extractions of cellular lipids and analysis by HPLC as below. For loading of CHO cells with LDL cholesterol, CHO-apoE cells were pre-incubated with 5 μM compactin and 50 μM mevalonate in the presence of 10 % LPDS for 16 h to down-regulate HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase activity and induce LDL receptor expression [23, 24] . The cells were then incubated with 50 μg/ml LDL in the presence of compactin, mevalonate and LPDS for another 24 h. Cells were then washed and incubated in serum-free medium to measure apoE secretion.
For the HMDMs, the cells were incubated with the LXR (liver X receptor) α and LXRβ ligand T0901317 (1 μM) for 24 h to maximize apoE gene expression [25] before cholesterol enrichment, in order to selectively assess the effect of cholesterol on post-transcriptional processing. The cells were then enriched with cholesterol by incubation in RPMI 1640 medium containing 10 % LPDS, 20 μg/ml chol/CD, 5 μg/ml ACATi and T0901317 for 16 h.
CHO-GFP-VSVGt cells were incubated at 40
• C for 16 h in DMEM/F12 medium with 5 % LPDCS, washed, and then incubated in fresh DMEM/F12 medium with 5 % LPDCS with or without 20 μg/ml chol/CD at 40
• C for a further 2 h. 'Low', 'intermediate' and 'high' cholesterol loading was achieved by incubating without chol/CD, with chol/CD for 1 h or with chol/CD for 2 h respectively, before chase experiments at 32
• C. In all of the experiments cell viability was monitored using microscopy, and measurements of cell protein and LDH release were as described previously [21] .
Measurement of secreted, cellular and apoE mRNA
ApoE secreted into the medium was measured by ELISA and confirmed by Western Blot analysis as described previously [21] . To determine the buoyant density of secreted apoE, media samples were subjected to sucrose density ultracentrifugation on a 1.33-65 % sucrose gradient as described previously [21] . Cellular apoE levels and apoE in the density fractions were determined by Western blot analysis [21] . In short, equal amounts of protein were separated on 4-12 % NuPage BisTris gels (Invitrogen) and apoE or α-tubulin were identified using anti-apoE (Millipore) and anti-α-tubulin (Sigma) antibodies. ApoE mRNA levels were determined by real-time PCR as described previously [21] .
Measurement of FC and CE content
The mass of FC and CE in cells and media were determined by reverse-phase HPLC after extraction into methanol/hexane as described previously [18, 26] .
Determination of SREBP-2 processing
SREBP-2 processing was determined as described previously [22] . Metabolic labelling was carried out as described previously [16] . In short, cells were incubated with methionine/ cysteine-free DMEM (Invitrogen) containing 500 μCi/ml [ 35 S]methionine/cysteine (PerkinElmer) for 1 h, then washed twice and incubated with F12 medium containing 0.1 % BSA for 2 h. 35 S-labelled apoE in the cell lysates and medium was immunoprecipitated using a goat antibody against human apoE (MilliPore) and Protein A-Sepharose (Amersham) and was separated by SDS/PAGE (4-12% gel). The 34 kDa band was quantified by phosphorimaging (Photostimulated Luminescence, Fujix BAS-1000).
2-DE (two-dimensional gel electrophoresis)
To detect individual apoE glycoforms, apoE was subjected to 2-DE as described previously [27] .
Microscopy
CHO-GFP-VSVGt cells were fixed with 4 % paraformaldehyde and permeabilized with 0.1 % Triton X-100 in blocking buffer (PBS containing 0.1 % BSA). Slides were washed then mounted in a mixture of the anti-fading medium Mowiol 4-88 (Calbiochem) and glycerol with the addition of DABCO (1,4-diazadicyclo[2.2.2]octane; Sigma). The images were captured using an Olympus FV1000 confocal laserscanning microscope equipped with a ×60 oil-immersion objective. For quantification of the mean fluorescent intensity of the Golgi and ER areas, images from different treatment groups were captured under identical settings. Mean fluorescent intensities in the Golgi area and in the area not associated with the Golgi were determined using ImageJ 1.41m (http://rsbweb.nih.gov/ij/). The total cell area was determined using DIC (differential interference contrast). A total of 50 cells per treatment group were analysed and the data were expressed as the ratios of mean fluorescence in the Golgi area/ mean fluorescence in the area not associated with the Golgi (ER). The same analysis was repeated in separate experiments by staining with the cis-Golgi marker GM130 (BD Biosciences) and using GM130-positive area to define the Golgi. Staining was performed as described previously [16] . Co-localization was determined by Pearson's correlation coefficients on 30 cells per condition using the JACoP plugin of ImageJ.
Data analysis
Results are presented either as means + − S.D. for three independent experiments or as means + − S.E.M. of multiple (n) experiments as indicated. A significant difference between control and multiple treatment groups was assessed by ANOVA using Dunnett's posthoc test. Comparisons of the means of two groups were performed using an unpaired Student's t test or Mann-Whitney U test as appropriate for parametric and non-parametric data respectively. All of the P values were two-tailed and P < 0.05 was considered significant.
RESULTS

Chol/CD complexes increase ER cholesterol levels in CHO cells
CHO-K1 cells stably expressing human apoE (CHO-apoE) were incubated with 20 μg/ml chol/CD complexes in the presence of LPDS for up to 16 h without perturbing cell viability. Chol/CD complexes increased cellular FC content on average from 29 + − 3 to 51 + − 2 nmol/mg cell protein after 16 h (mean + − S.E.M., P < 0.01, n = 6 independent experiments) ( Figure 1A ). CE accumulation is an indicator of cholesterol transport to, and esterification in, the ER [28] . CE content was negligible in the control cells and increased to 31 + − 3 nmol/mg cell protein (P < 0.001) after cholesterol enrichment, confirming transport of cholesterol into the ER ( Figure 1A ). As expected, in the presence of ACATi total cholesterol accumulation was similar, but intracellular FC increased (74 + − 4 nmol/mg cell protein, P < 0.001, n = 6), and CE returned to control levels (1.2 + − 0.1 nmol/mg cell protein). These data show that cholesterol delivered via chol/CD complexes accumulates intracellularly and is assessable to ACAT in the ER. To independently confirm that cholesterol levels in the ER were increased under these conditions, SREBP-2 processing was investigated. Previous studies using CHO cells have shown that when ER cholesterol exceeds 5 % of the total ER lipids SREBP-2 transport to the Golgi is blocked, resulting in a lack of SREBP-2 processing [29] . Incubation of CHO-apoE cells with chol/CD complexes inhibited SREBP-2 processing ( Figure 1B) . Cleavage of SREBP-2 was completely prevented in the presence of ACATi, confirming significant cholesterol accumulation in the ER.
Excess cholesterol loading in the ER is known to induce an ER stress response [30] . We therefore investigated whether the cholesterol accumulation achieved under these conditions induced some degree of ER stress, as additional evidence for the accumulation of cholesterol in the ER. As positive controls, classical inhibitors of the ER stress response, Tun, Thaps and DTT, were used. These all strongly induced phosphorylation of IRE1α, expression of GADD34 and phosphorylation of eIF2α, confirming activation of the classical ER stress pathways ( Figure 1C ). Cholesterol enrichment by chol/CD complexes or chol/CD complexes plus ACATi also induced phospho-IRE1α and phospho-elF2α, although this was less pronounced than was observed with the classical ER stress inducers ( Figure 1C ). GADD34 was mildly induced by loading with chol/CD complexes (with or without ACATi), with no significant difference between cholesterol loading conditions. The induction of GADD34 expression following cholesterol loading was mild in comparison with the marked increase achieved by the classical ER stress inducers. Taken together, these data clearly demonstrate cholesterol enrichment of the ER compartment after incubation of CHO cells with chol/CD.
Cholesterol accumulation decreases apoE levels in the medium
We have previously shown that CHO cells expressing human apoE under a CMV promoter (CHO-apoE) provide a useful model to study apoE biology [16] . After incubation with chol/CD complexes, the amount of apoE in the medium was decreased by 57 + − 9 % (P < 0.001, n = 6) and by 66 + − 2 % (P < 0.001, n = 6) in the presence of ACATi (Figure 2A) . A trend towards less apoE in the medium was achieved during inhibition of ACAT, consistent with a role for increasing intracellular free cholesterol levels in this process. Concurrently, cellular apoE levels increased 1.8 + − 0.2-fold (P < 0.01, n = 6) and 2.6 + − 0.2-fold (P < 0.001, n = 6) after incubation of chol/CD complexes without and with ACATi respectively (Figure 2B ), suggesting that apoE that is not secreted in response to cholesterol enrichment is, at least in part, accumulated intracellularly.
ApoE secretion is tightly linked to cellular cholesterol status (reviewed in [31] ). It has been reported that apoE particles secreted from CHO cells and human macrophages are similar [32] , and that apoE secreted from CHO cells is partly lipidated and floats between 1.12 and 1.21 g/ml [16] . To investigate whether cholesterol accumulation affects the lipidation of apoE, the buoyant density of secreted apoE from cholesterol-enriched cells was determined and compared with that of apoE secreted from non-loaded cells. In agreement with our previous report [16] , secreted apoE floated between a density of 1.12 and 1.21 g/ml. Cholesterol enrichment did not affect this lipidation pattern of secreted apoE ( Figure 2C ).
To fully exclude an effect of cholesterol loading on apoE synthesis under these conditions, and to confirm that the observed effects are related to the cellular processing of pre-formed apoE, the proteins in cells pre-loaded with cholesterol were radiolabelled with [
35 S]methionine/cysteine for 1 h, washed and chased in cold medium, and the secreted and cellular levels of pre-labelled [ 35 Figures 2D and 2E) , indicating that the effects of cholesterol loading on apoE occurred post-translationally.
Inhibition of protein secretion is not restricted to a single cell type or to a single method of cholesterol enrichment
We next investigated whether the inhibition of apoE secretion was restricted to the route of cholesterol delivery or the cell type, by studying CHO-apoE cells enriched with LDL cholesterol and primary HMDMs enriched with chol/CD. As cells normally regulate intracellular free cholesterol levels very tightly, CHO-apoE cells were pre-treated with compactin and mevalonate to inhibit cholesterol synthesis and increase LDL receptor expression as described previously [23, 24] . CHOapoE cells incubated with LDL accumulated FC and CE and demonstrated decreased apoE levels in the medium (Figure 3 ), similar to that observed after incubation with chol/CD complexes.
HMDMs, which constitutively express and secrete apoE, were incubated with chol/CD complexes in the presence of ACATi both under normal conditions and after treatment with the LXR ligand T0901317 to maximize apoE gene expression [25] . Under these conditions, apoE mRNA levels were not affected by cholesterol accumulation ( Figure 4A ). Chol/CD increased cholesterol levels 1.8-fold (P < 0.001) and this resulted in a 42 + − 6 % (P = 0.01) reduction in apoE levels in the medium (Figures 4B and 4C) . The HMDM experiments were repeated without the LXR ligand T0901317 and identical results were seen (results not shown). These data indicate that the effects are not restricted to a single cell type or to a single method of cholesterol enrichment.
Comparison of buoyant density of secreted apoE showed that apoE secreted from HMDMs predominantly floats at a similar density to apoE secreted from CHO cells ( Figure 4D ), and that cholesterol enrichment did not affect lipidation of secreted apoE from HMDMs.
The effect of cellular cholesterol accumulation on apoE secretion is reversible
We next determined whether the effect of cholesterol accumulation was to induce irreversible cytotoxicity, or whether removal of accumulated cholesterol could restore apoE release into the medium. Treatment of cholesterol-enriched CHOapoE cells with 0.5 % β-methyl CD effectively decreased the cellular cholesterol levels to those of non-enriched cells (e.g. from 94 + − 8 nmol/mg cell protein in cholesterol-enriched cells to 30 + − 8 nmol/mg cell protein after CD treatment of cholesterol-enriched cells, compared with 30 + − 1 nmol/mg cell protein in non-loaded control cells) ( Figure 5A ). Removal of cholesterol restored apoE levels in the medium to levels similar to those of non-loaded cells ( Figure 5B ). The accumulation of intracellular apoE after cholesterol loading was also reversed by removal of excess cholesterol ( Figure 5C ). Although CD
Figure 4 Cholesterol accumulation decreases apoE secretion in primary human macrophages
Isolated human monocytes were differentiated into macrophages and treated with 1 μM T0901317 for 24 h before cholesterol loading with 20 μg/ml chol/CD in the presence of 5 μg/ml ACATi for 16 h. Cells were washed and incubated with medium containing 0.1 % BSA for 2 h. ApoE mRNA levels (A), FC content (B), apoE levels in extracellular medium (C) and buoyant density of secreted apoE (D) were determined by real-time PCR, HPLC, ELISA and sucrose density ultracentrifugation as described in the Experimental section. added to non-loaded control cells decreased the basal FC levels significantly ( Figure 5A ), apoE levels in the medium were not affected ( Figure 5B ). This suggests that the release of apoE into the medium is not directly stimulated by CD exposure, but is restored by the removal of excess cellular cholesterol from cholesterolenriched cells by CD vehicle.
Cholesterol accumulation inhibits apoE glycosylation and sialylation
ApoE is extensively glycosylated and sialylated during transit through the Golgi [33, 34] . The resulting multiple glycoforms, with increasing molecular mass and decreasing pI, are thus useful indicators of intracellular transport and processing through the Golgi network. 2-DE showed the presence of multiple apoE glycoforms with different molecular mass and pI values ( Figure 6A ). Cleavage of sialic acid residues using α-(2→3,6,8,9)-neuraminidase eliminated the appearance of high molecular mass, low pI value spots confirming that the charge of apoE glycoforms in these CHO-apoE cells was conferred by sialic acid residues. After exposure of CHO-apoE cells to chol/CD, we noted that higher molecular mass bands of apoE were no longer present in 1-DE (one-dimensional gel electrophoresis; Figure 2B , arrow on inset). This was supported by 2-DE, whereby cholesterol loading markedly perturbed apoE glycoform distribution with a complete loss of the high molecular mass sialylated apoE glycoforms and an accumulation of apoE in less glycosylated non-sialylated glycoforms after cholesterol loading ( Figure 6B ). The 2-DE profile after cholesterol enrichment was similar to that after treatment of apoE from the control cells with neuraminidase ( Figure 6A ). As chol/CD treatment does not affect the activity of glycosylation enzymes [15] , these data are consistent with a cholesterol-induced block in transport at the level of the ER or early Golgi compartments.
BFA causes redistribution of resident Golgi proteins, including glycosylation enzymes to the ER [35] , but has been shown previously to inhibit the glycosylation and sialylation of apoE [34] . To test whether BFA could restore the inhibition of glycosylation of apoE after cholesterol accumulation, chol/CD and ACATi-treated cells were treated with BFA. BFA exposure inhibited cellular glycosylation and sialylation of apoE, and did not restore glycosylation and sialylation of apoE in cells which had been enriched with cholesterol (Supplementary Figure S1 at http:// www.BiochemJ.org/bj/447/bj4470051add.htm). These results confirm data previously observed by others [34] , showing that BFA inhibits the formation of higher molecular mass sialylated apoE glycoforms. The failure of BFA to restore glycosylation and sialylation of apoE implies that the processing of apoE into higher molecular mass isoforms occurs within the TGN, which does not collapse on to the ER upon BFA treatment [36] .
Cholesterol accumulation inhibits transport from ER to Golgi of transmembrane VSVGt protein
The transmembrane VSVGt protein is widely used to visualize protein traffic from the ER to the Golgi and through the Golgi network [6, 14, 37] . At 40
• C VSVGt reversibly misfolds, resulting in ER accumulation. Traffic can resume at 32
• C with VSVGt moving from the ER to a juxtanuclear Golgi complex.
Initial studies confirmed that CHO-GFP-VSVGt cells accumulated cholesterol after exposure to chol/CD, increasing intracellular cholesterol levels from 25 + − 1 nmol/mg cell protein (control) to 46 + − 7 nmol/mg cell protein (intermediate cholesterol loading) and 86 + − 6 nmol/mg cell protein (high cholesterol loading) after incubation with chol/CD and ACATi for 1 and 2 h respectively, which were comparable with the levels achieved in CHO-apoE cells.
Under the control conditions without cholesterol enrichment, incubation at 40
• C resulted in a typical ER localization of VSVGt ( Figure 7A ; [4, 37] ). After a 20 min incubation at 32
• C, VSVGt showed some Golgi localization in the control cells with partial retention of VSVGt within the ER, and, after 40 min at 32
• C, most of the VSVGt had moved from the ER to the Golgi confirming normal ER to Golgi traffic in this system. After cholesterol enrichment, the traffic of VSVGt from the ER to the Golgi was decreased with more VSVGt retained in the ER, especially under conditions of greater cholesterol accumulation ( Figure 7A , righthand panels). In agreement with previous reports, we observed that cholesterol accumulation resulted in a slight dispersal of the Golgi stacks [6] . The mean fluorescent intensity of GFPVSVGt within the Golgi area relative to that in the non-Golgi (ER) area (Golgi/ER ratio) increased from 19 + − 3 at 20 min to 42 + − 5 after 40 min (P < 0.0001) in the control cells, consistent with ER to Golgi transport. Movement of VSVGt was significantly inhibited by cholesterol accumulation, with Golgi/ER ratios at 40 min of 23 + − 3 (P < 0.0001 relative to the control) and 7 + − 2 (P < 0.0001 relative to the control), after intermediate (1 h of chol/CD exposure) and high (2 h of chol/CD exposure) levels of cholesterol enrichment respectively ( Figure 7B) .
Under normal conditions, processing of N-glycans in the Golgi renders VSVGt resistant to endo H (endoglycosidase H) cleavage [14] . To further investigate whether VSVGt trafficked normally through the Golgi under conditions of cholesterol enrichment, endo H cleavage of VSVGt was studied. Endo H treatment of control and high cholesterol-containing cells showed that all of the VSVGt present at zero time was accessible to endo H ( Figure 7C ), consistent with the ER localization of VSVGt. After 40 min of trafficking at 32
• C, a proportion of VSVGt in the control cells was resistant to endo H cleavage (lane 6). However, in cholesterol-loaded cells all VSVGt was accessible to endo H (lane 8), supporting inhibition of ER to Golgi transport of VSVGt after cholesterol accumulation.
To confirm VSVGt was redistributed to the Golgi under these conditions, cells were co-stained with the cis-Golgi marker GM130 after 40 min at 32
• C ( Figure 7D ). This supported our visual impression that the Golgi was well preserved and only minimally dispersed under conditions of cholesterol enrichment. There was a high degree of co-localization between VSVGt and GM130 in the control conditions when quantified using Pearson's correlation (R r = 0.88 + − 0.03; n = 30 cells), and this was significantly decreased with cholesterol enrichment (R r = 0.71 + − 0.05; n = 30 cells, P < 0.0001 relative to the control), confirming that cholesterol caused partial retention of VSVGt outside the GM130-positive compartment. The Golgi/ER ratio after 40 min at 32
• C of GFP-VSVGt, using the GM130-positive area to define the Golgi region, was markedly decreased by cholesterol enrichment (P < 0.0001; Figure 7E ), confirming our earlier analysis. These results clearly demonstrated that cholesterol accumulation inhibits ER to Golgi protein traffic.
DISCUSSION
We have demonstrated by independent techniques that intracellular cholesterol accumulation can inhibit ER to Golgi transport and provide the first evidence that this can inhibit the secretion of an important mammalian secreted glycoprotein, apoE. These data have important implications for the integrity of cellular transport pathways under conditions of cholesterol excess, such as atherosclerosis and Alzheimer's disease.
The reported effects of increased cholesterol levels in the ER on protein transport and secretion have been highly variable. One study indicated a block in the exit of VSVGt from the TGN, but only studied short-term cholesterol exposure without demonstrating accumulation of cholesterol in the ER compartment [6] . Others have shown that sterols block binding of COPII (coatamer protein II) to SCAP and control SCAP sorting in the ER without directly affecting VSVGt entry into COPII vesicles [38] . Under our experimental conditions, CHO-apoE cells clearly accumulated cholesterol in the ER compartment as shown by three independent techniques: the ACAT-dependent accumulation of cholesteryl esters, the alteration in SREBP processing, and the induction of the ER stress response. Under these conditions, ER cholesterol accumulation perturbed ER to Golgi transport. In the case of apoE, a block in trafficking from the ER to the Golgi was supported by the decreased abundance of higher molecular mass and sialylated apoE glycoforms. In the case of VSVGt, a cholesterol-induced block in the ER to Golgi transport was confirmed by both microscopy and biochemical techniques.
ApoE is known to be predominantly secreted from cells such as macrophages as a phospholipid disc and with lipoprotein densities varying from 1.06-1.21 g/dl [16, 39] . Previous studies have shown that CHO cells and macrophages secrete apoE in similar particles [32] , and in the present study we confirm a similar lipoprotein density of secreted apoE from CHO cells and HMDMs. Importantly, the density of secreted apoE was not affected by cholesterol enrichment, indicating that the inhibition of apoE secretion we have observed is unlikely to be due to effects of cholesterol on the lipidation of apoE during intracellular processing. Given the perturbation of VSVGt transport we observed, inhibition of apoE transport upstream of its lipidation is probable.
Some [4] , but not all [2, 38] , previous studies have suggested that a relative deficiency of cholesterol delays VSVGt transport from the ER to the Golgi. In addition, cholesterol depletion was shown to inhibit exit of both constitutive and regulated secretory proteins from the TGN [5, 6] . Under our experimental conditions, a relatively mild depletion of cholesterol levels to below the baseline level by exposure of control CHO cells to a CD vehicle (without cholesterol) had no effect on apoE secretion, whereas depletion of excess cholesterol restored apoE secretion to normal. Thus the findings of the present study appear to be restricted to the effects of cholesterol excess.
Cholesterol is understood to follow distinct pathways to the plasma membrane and to the ER [28] , and ER cholesterol is known to be critical for induction of cellular injury [8] . The present study indicated that, although cholesterol accumulation showed mild increases in ER stress markers, induction of ER stress may not of itself be sufficient to inhibit apoE secretion. In preliminary studies, the inducers of ER stress DTT and tunicamycin did not block apoE secretion or change apoE glycoform distribution (results not shown). Thus distinct components of ER exit must be affected by ER stress inducers, such as excess cholesterol, in order to provoke the block in transport we have observed. Cholesterol enrichment by two independent routes, chol/CD and LDL, inhibited apoE secretion, suggesting a general effect of ER cholesterol enrichment that is not restricted to delivery via CDs. Importantly, cholesterol inhibited apoE secretion in primary human cells constitutively expressing apoE (HMDMs), indicating that this phenomenon is not restricted to CHO cells. As FC accumulation to the point of generation of FC crystals and the ER stress response have been well documented in macrophage foam cells and atherosclerotic plaques [8, 40, 41] , it is quite probable that the effects we have observed in the present study in relation to apoE secretion occur in vivo. The present study may also provide a mechanistic explanation for the apparently reduced secretion of apoE from cholesterol-enriched foam cell macrophages in vivo [42] .
At this stage, it is unclear whether cholesterol accumulation exerts a general effect on protein transport and secretion, as implied by similar results with VSVGt and apoE, or is selective. Preliminary studies in our laboratory indicate that cholesterol accumulation variably affects the secretion of constitutively secreted proteins from human macrophages. For example, the constitutively secreted granule protein lysozyme is secreted normally after cholesterol enrichment (results not shown). Further studies are required to determine the range of protein cargoes which may be affected by cholesterol accumulation. Although the results of the present paper provide strong support to the general principle that cholesterol accumulation can perturb intracellular protein transport and secretion, additional studies will be required to clarify whether intracellular apoE and VSVGt transport are identical or how indeed they differ.
Extracellular apoE promotes cholesterol efflux [43] and antigen presentation [44, 45] , regulates macrophage phenotype [46] and is antiproliferative towards smooth muscle cells [47] . All of these processes are likely to be perturbed by 'frustrated' secretion [48] . Importantly, our data indicate that despite the presence of ER stress, apoE secretion can be restored by depletion of excess cholesterol, and strategies to normalize ER cholesterol content in vivo may restore normal homoeostatic processes and intracellular protein transport.
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